Phase 2b study completed in amyotrophic lateral sclerosis (ALS) demonstrated lead asset PrimeC slows disease progression and functional decline Ongoing partnership discussions to advance PrimeC to Phase 3 study in ALS and commercialization Phase 3 study design for PrimeC in ALS aligned...
Read More Details
Finally We wish PressBee provided you with enough information of ( NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates )
Also on site :
- Hammerspace, an unstructured data wrangler used by Nvidia, Meta and Tesla, raises $100M at $500M+ valuation
- India’s exports reach record high
- Spirometry Predicts Pre-COPD State Regardless of Smoking